RXRX

Recursion Pharmaceuticals
$3.01
+$0.05 (+1.69%)Jul 27, 2026
1.0PoorMoatMint rating

MoatMint rates Recursion Pharmaceuticals (RXRX) 1.0 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 1.5 out of 10.

Key metrics

The numbers that frame RXRX today
Market cap
$1.60B
P/E (TTM)
-2.8
EV / FCF
-3.1
Gross margin
7.2%
EV / Sales
15.2
ROIC
-311.6%
Div yield
0%
Debt / equity
0.1
52wk Low
$2.77
52wk High
$7.18

RXRX stock rating

How RXRX scores on quality, value, growth, momentum and financial health
1.0out of 10
Low overallNeutral business, expensive priceTop 90% of ~5,000 US stocks
QualityPoor1.5/10
GrowthNeutral4.7/10
MomentumPoor1.9/10
ValuePoor0.9/10
Financial HealthFair3.6/10

Growth

Revenue and earnings trend for RXRX
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about RXRX
Is Recursion Pharmaceuticals a good buy?
No. Recursion Pharmaceuticals has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks mixed. The support signal is useful, but not decisive. We think Recursion Pharmaceuticals is selling at a very high price.
What is the market capitalization of RXRX?
Recursion Pharmaceuticals's market capitalization is $1.60B.
What is the P/E ratio for RXRX stock?
Recursion Pharmaceuticals's current P/E ratio is -2.8.
What is the 52-week high for RXRX stock?
The 52-week high for Recursion Pharmaceuticals is $7.18. The current close of $3.01 is 58.1% below that high.
What is the 52-week low for RXRX stock?
The 52-week low for Recursion Pharmaceuticals is $2.77. The current close of $3.01 is 8.7% above that low.
Does RXRX stock pay dividends?
Recursion Pharmaceuticals does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RXRX?
Recursion Pharmaceuticals's Debt / Equity ratio is 0.07.